中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 自动化研究所
  3. 中国科学院自动化研究所
  4. 多模态人工智能系统全国重点实验室
  5. 计算生物学与机器智能
PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials

文献类型：期刊论文

作者Luo, Jichang8,9; Liao, Wanying7; Wang, Xue6; Xu, Ran8,9; Li, Wei5; Li, Wenjing4; Liu, Kan3; Huang, Kaixun2; Ma, Yan8,9; Wang, Tao8,9
刊名BMJ OPEN
出版日期2022-11-01
卷号12期号:11页码:6
ISSN号2044-6055
关键词VASCULAR MEDICINE CLINICAL PHARMACOLOGY Coronary heart disease Lipid disorders Protocols & guidelines
DOI10.1136/bmjopen-2022-062046
通讯作者Yang, Bin(yangbin_81@163.com) ; Jiao, Liqun(liqunjiao@sina.cn)
英文摘要IntroductionAtherosclerosis is the leading cause of cardiovascular disease (CVD), which is one of the most common causes of morbidity and mortality worldwide. Lipid accumulation and inflammation play a crucial role in the pathogenesis of atherosclerosis. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an emerging lipid-lowering agent reported as a potential anti-inflammation effect in the prevention of CVD. However, the anti-inflammatory effect is still elusive. Therefore, a systematic review and meta-analysis is needed to analyse the anti-inflammatory effect of PCSK9 inhibitors on atherosclerosis in practice. Methods and analysisThis protocol was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. We will include double-blind, randomised controlled trials that reported changes in the levels of inflammatory markers, with an intervention arm of PCSK9 inhibitors and a treatment duration of more than 2 weeks. The following databases will be mainly searched from 1 January 2003 to the formal search date: PubMed, Embase, Web of Science and the Cochrane Central Register of Controlled Trials. The primary aim is to assess the effect of PCSK9 inhibitors on inflammatory markers, including circulating inflammatory markers such as C-reactive protein, high-sensitivity C-reactive protein, white cell counts, IL-1 beta, IL-6 and TNF-alpha and local inflammatory markers such as the most diseased segment target-to-background ratio of the index vessel in adult patients with atherosclerosis. We will assess the quality of evidence, heterogeneity and report bias following the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions. Ethics and disseminationDue to the systematic review being based on published studies, no ethics approval is required. The study results will be presented at international conferences and published in a peer-reviewed journal. PROSPERO registration numberCRD42022297710.
WOS关键词HIGH-RISK ; CHOLESTEROL ; ROSUVASTATIN ; EVOLOCUMAB ; DISEASE ; STATIN
资助项目Beijing Science and Technologic Project[Z201100005520019]
WOS研究方向General & Internal Medicine
语种英语
出版者BMJ PUBLISHING GROUP
WOS记录号WOS:000891257700014
资助机构Beijing Science and Technologic Project
源URL[http://ir.ia.ac.cn/handle/173211/51302]  
专题模式识别国家重点实验室_计算生物学与机器智能
通讯作者Yang, Bin; Jiao, Liqun
作者单位1.Capital Med Univ, Xuanwu Hosp, Dept Intervent Radiol, Beijing, Peoples R China
2.Sun Yat Sen Univ, Affiliated Hosp 8, Shenzhen, Peoples R China
3.Hunan Univ Chinese Med, Hosp 1, Changsha, Hunan, Peoples R China
4.Chinese Acad Sci, Natl Lab Pattern Recognit, Inst Automat, Beijing, Peoples R China
5.Liaocheng Peoples Hosp, Dept Neurosurg, Liaocheng, Shandong, Peoples R China
6.Capital Med Univ, Xuanwu Hosp, Med Lib, Beijing, Peoples R China
7.Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing, Peoples R China
8.Capital Med Univ, Dept Neurosurg, Xuanwu Hosp, Beijing, Peoples R China
9.China Int Neurosci Inst China INI, Beijing, Peoples R China
推荐引用方式
GB/T 7714		 Luo, Jichang,Liao, Wanying,Wang, Xue,et al. PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials[J]. BMJ OPEN,2022,12(11):6.
APA Luo, Jichang.,Liao, Wanying.,Wang, Xue.,Xu, Ran.,Li, Wei.,...&Jiao, Liqun.(2022).PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials.BMJ OPEN,12(11),6.
MLA Luo, Jichang,et al."PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials".BMJ OPEN 12.11(2022):6.

入库方式： OAI收割

来源：自动化研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。